基因素脱乙酶抑制剂沃里诺斯塔特与二氧化碳无水酶II和IX的脱结合
Mitchell C Gulkis1, James T Hodgkinson2, Céleste P Sele3
1Department of Biochemistry and Molecular Biology, University of Florida, 1149 Newell Drive, Gainesville, FL 32610, USA.
概括
一种癌症药物沃里诺斯塔特 (SAHA) 可能与碳酸无水酶 (CA) 结合,可能导致副作用. 这项研究揭示了SAHA.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 药用化学 医学化学
背景情况:
- 像Vorinostat (SAHA) 这样的基因组脱乙酶抑制剂 (HDACi) 在癌症治疗中使用.
- 由于SAHA缺乏同型选择性,它可以通过抑制依赖的酶来引起非目标效应.
- 碳酸无水酶 (CA) 是金属酶,可能是意想不到的目标.
研究的目的:
- 为了研究SAHA与人类的碳酸酶II (CA II) 和碳酸酶IX (CA IX) 结合的结构基础.
- 探索SAHA与CA的潜在非目标相互作用.
- 评估基于酸盐的化合物作为新型CA抑制剂的潜力.
主要方法:
- 在室温和100K的高分辨率晶体学.
- 瑞士码头建模用于预测绑定方向.
- 使用纳米DSF进行热转移测定.
- 具有约束力的计算.
主要成果:
- SAHA与CA II和CA IX模仿物结合,采用不同的符合物并与离子协调.
- 由于氨基酸变异,在CA II和CA IX模仿之间观察到疏水相互作用的差异.
- 瑞士码头准确地预测了SAHA的绑定姿势.
- 与乙醇胺不同的是,SAHA显示CA的稳定性很小.
- 绑定能量的计算表明,SAHA可能与其HDAC目标相似的亲和力结合CA.
结论:
- 萨哈可以与碳酸无水酶结合,可能导致临床副作用.
- 胺代表了开发新型非硫胺类CA抑制剂的潜在支架.
- 实现CA抑制剂的异型选择性仍然是一个重大挑战.
相关概念视频
Drug Binding to Blood Components
249
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
249
Protein-Drug Binding: Mechanism and Kinetics
931
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
931
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
440
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
440
Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446


